Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $349,770 - $521,095
44,500 Added 28.71%
199,500 $1.68 Million
Q2 2022

Aug 15, 2022

BUY
$7.06 - $25.52 $1.09 Million - $3.96 Million
155,000 New
155,000 $1.23 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Tri Locum Partners LP Portfolio

Follow Tri Locum Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Tri Locum Partners LP with notifications on news.